Clinical trial NCT04587375: Diagnosis of Endocrine Dysfunctions in Covid-19
Official title: Diagnosis of Endocrine Dysfunctions in Covid-19 : Explorations of the Plasma Renin and Aldosterone Levels in Patients With Covid-19 Infection.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Covid 19
Keywords: Covid-19
Renin Angiotensin Aldosterone System
Hormon disorders
Lead sponsor: University Hospital, Montpellier
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with Covid-19 diagnosis hospitalized in Montpellier University hospital

Brief summary: As observed with SARS-CoV responsible for SARS 2003, the new coronarovirus SARS-CoV-2 uses the angiotensin converting enzyme type 2 (ACE2) as cellular receptor to infect cells. The renin aldosterone angiostensin system (RAAS) has known effects in the lungs: some receptors are pro-inflammatory, others are anti-inflammatory. Thus the deregulation of the RAAS induced by the SARS-CoV-2 could explain the inflammatory response of Covid-19 infection and be a modulator of the severity of its course.

Furthermore, the SARS 2003 experience suggests that there may be others endocrine involvment, particularly an failure on the hypothalamus-pituitary and adrenal axis. Indeeed, cases of hypocorticism and hypothyroidism of central origin were described.

Altogether, the endocrine system might play a role both in the pathophysiology of Covid-19 infection and in the activity and severity of the disease.

In this study, the investigators proposed to explore endocrine functions on biological samples in a series of patients admitted for Covid-19 in our clinic.


Eligibility criteria: Inclusion criteria:

- Patients with Covid-19 diagnosis and hospitalized in our clinic

Exclusion criteria:

- Minor patient

Primary outcomes:
measure: Plasma aldosterone levels
timeFrame: 1 day (at inclusion)
measure: Plasma renin levels
timeFrame: 1 day (at inclusion)
Secondary outcomes:
measure: covid-19 infection severity
timeFrame: 1 day (at inclusion)
measure: Maximum severity of Covid-19 infection
timeFrame: 1 day (at inclusion)
measure: Plasma aldosterone level
timeFrame: 1 day (at the end of hospitalization)
measure: Plasma ACTH level
timeFrame: 1 day (at the end of hospitalization)
measure: Plasma cortisol level
timeFrame: 1 day (at inclusion)
measure: Plasma cortisol level
timeFrame: 1 day (at the end of hospitalization)
measure: Plasma T3l level
timeFrame: 1 day (at the end of hospitalization)
measure: Plasma T3l level
timeFrame: 1 day (at inclusion)
measure: Plasma ACTH level
timeFrame: 1 day (at inclusion)
measure: Plasma LH level
timeFrame: 1 day (at inclusion)
measure: Plasma LH level
timeFrame: 1 day (at the end of hospitalization)
measure: Plasma DHEA level
timeFrame: 1 day (at the end of hospitalization)
measure: Plasma DHEA level
timeFrame: 1 day (at inclusion)
measure: Plasma estradiol (female) or testosterone (male) level
timeFrame: 1 day (at the end of hospitalization)
measure: Plasma estradiol (female) or testosterone (male) level
timeFrame: 1 day (at inclusion)
measure: Plasma FSH level
timeFrame: 1 day (at the end of hospitalization)
measure: Plasma FSH level
timeFrame: 1 day (at inclusion)
measure: type of treatments
timeFrame: 1 day
measure: Clinical characteristics
timeFrame: 1 day
measure: radiological characteristics
timeFrame: 1 day
Other outcomes:
Locations:
city: Montpellier
country: France
facility: Uhmontpellier
Study officials:
affiliation: University Hospital, Montpellier
name: Philippe GUILPAIN, MD, PhD
role: STUDY_DIRECTOR
References: